Trial Profile
Long-term extension study of the safety and efficacy of ibrutinib oral monotherapy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Sep 2014
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 10 Sep 2014 New trial record